Loading clinical trials...

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | Clinical Trials | Clareo Health

NO_LONGER_AVAILABLE

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

68Ga-DOTATATE Imaging in Neuroendocrine Tumors

NCT02174679•Jonsson Comprehensive Cancer Center

Summary

To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Detailed Description

This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Older than 18 years the time of radiotracer administration
•Provides written informed consent
•Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline
•Able to remain still for duration of each imaging procedure (about 30 minutes)

Exclusion Criteria

•Less than 18 years-old at the time of radiotracer administration
•Pregnant or nursing
•Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
•Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.

Locations (1)

UCLA Hospital

Los Angeles, California, United States

Key Dates

Last Updated

July 27, 2020

Conditions

Carcinoid CancerNeuroendocrine TumorsMedullary Thyroid CancerCancers Expressing Somatostatin Receptors

Interventions

68Ga DOTATATE

DRUG

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208

Neuroendocrine TumorsWell-Differentiated Neuroendocrine Carcinoma+1 more

View study

RECRUITINGPHASE2

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

NCT06228066

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 27, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Inclusion Criteria

Exclusion Criteria

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Natural History Study of Children and Adults With Medullary Thyroid Cancer

F-Tryptophan PET/CT in Human Cancers

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)